CD15 Antibody (VIM-C6): sc-59533
- CD15 Antibody (VIM-C6) is a mouse monoclonal mouse IgM κ κ, cited in 1 publications, provided at 200 µg/ml
- recommended for detection of CD15 of human origin by WB, IP, IF and FCM
- See CD15 (C3D-1): sc-19648 for CD15 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for CD15 Antibody (VIM-C6). This work is in progress.
QUICK LINKS
CD15 Antibody (VIM-C6) is a mouse monoclonal IgM antibody that detects CD15 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD15, also known as Lewis X or LeX, is a carbohydrate antigen synthesized by FucT-IV (alpha 1,3-fucosyltransferase IV) and is primarily located on the surface of leukocytes and certain tumor cells. This trisaccharide structure is crucial for its function as an adhesion molecule, facilitating calcium-mediated homotypic binding among cells. CD15 on the cell surface promotes strong self-aggregation, which is essential for various physiological processes, including immune response and inflammation. CD15 serves as a ligand for selectins, proteins that play a pivotal role in mediating leukocyte-specific interactions, thereby enhancing its importance in cell adhesion and migration during immune responses. CD15′s ability to mediate these interactions underscores its significance in both normal physiological functions and pathological conditions, making anti-CD15 antibody (VIM-C6) an invaluable tool for researchers studying cell adhesion mechanisms and their implications in health and disease.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD15 Antibody (VIM-C6) References:
- CD15 expression in mature granulocytes is determined by alpha 1,3-fucosyltransferase IX, but in promyelocytes and monocytes by alpha 1,3-fucosyltransferase IV. | Nakayama, F., et al. 2001. J Biol Chem. 276: 16100-6. PMID: 11278338
- Expression of the CD15 antigen on normal and leukemic myeloid cells: effects of neuraminidase and variable detection with a panel of monoclonal antibodies. | Ball, ED., et al. 1991. Mol Immunol. 28: 951-8. PMID: 1681429
- Multipotent CD15+ cancer stem cells in patched-1-deficient mouse medulloblastoma. | Ward, RJ., et al. 2009. Cancer Res. 69: 4682-90. PMID: 19487286
- Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer. | Giordano, G., et al. 2015. J Exp Clin Cancer Res. 34: 108. PMID: 26427914
- Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia. | Chisini, M., et al. 2017. Hematol Oncol. 35: 804-809. PMID: 27400753
- Role of CD15 expression in dysplastic and neoplastic tissue of the bile duct - a potential novel tool for differential diagnosis of indeterminate biliary stricture. | Walter, D., et al. 2016. Histopathology. 69: 962-970. PMID: 27442966
- Immature stroma and high infiltration of CD15+ cells are predictive markers of poor prognosis in different subsets of patients with pancreatic cancer. | Yamada, Y., et al. 2024. Cancer Sci. 115: 1001-1013. PMID: 38230840
- Modified CD15/CD16-CLL1 inhibitory CAR-T cells for mitigating granulocytopenia toxicities in the treatment of acute myeloid leukemia. | Zhang, R., et al. 2025. Transl Oncol. 52: 102225. PMID: 39647325
- Expression of the CD15 antigen (Lewis x) in breast cancer. | Brooks, SA. and Leathem, AJ. 1995. Histochem J. 27: 689-93. PMID: 8557532
- Engagement of the Lewis X antigen (CD15) results in monocyte activation. | Lo, SK., et al. 1997. Blood. 89: 307-14. PMID: 8978306
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD15 Antibody (VIM-C6) | sc-59533 | 200 µg/ml | $322.00 |